ATLASATLAS fair value
ATLAS has no fair value for this stock today.
AtriCure (ATRC)
AtriCure stock price today, ATLAS forecast and fair value
Healthcare · Medical Instruments & Supplies · NASDAQ
$61.08▲ +3.58%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on AtriCure in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On AtriCure
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives AtriCure a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $56.71 and $65.58; in 9 out of 10, between $49.86 and $74.60. Estimated annual volatility is 40%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $2.9B
- P/E ratio
- 270.9
- 52-week high
- $61.70
- 52-week low
- $25.36
- Revenue (12 months)
- $570M
- Revenue growth (YoY)
- +14.9%
- Gross margin
- 75.0%
- Operating margin
- -1.8%
- Net margin
- -2.1%
- Return on equity
- 2.2%
- Free cash flow (12 months)
- $48.8M
- Beta
- 1.26
What this means
ATLAS does not publish a fair value for ATRC right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks ATRC has traded between $25.36 and $61.70. Today it is 1.0% below that high and 141% above its low.
On the business: revenue grew 14.9% year over year; net margin is 2.1%; it trades at 270.9 times earnings.
Its beta is 1.26: it tends to move more than the market, both up and down.
About the company
AtriCure Inc. is a medical device company that develops and sells surgical technologies for treating atrial fibrillation, managing the left atrial appendage, and controlling post-operative pain.
Want to see everything about AtriCure?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does AtriCure do?
AtriCure Inc. is a medical device company that develops and sells surgical technologies for treating atrial fibrillation, managing the left atrial appendage, and controlling post-operative pain.
What is the chance ATRC goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, ATRC ends the month between $56.71 and $65.58.
How big is AtriCure and what is its P/E ratio?
AtriCure's market capitalization is $2.9B. Its price-to-earnings (P/E) ratio is 270.9: you pay $270.9 for each $1 of yearly earnings.
How volatile is ATRC?
ATLAS estimates annual volatility at 40%. In a typical month, half of the outcomes end between $56.71 and $65.58.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer